Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Gross Margin (2020 - 2025)

Historic Gross Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 72.4%.

  • GeneDx Holdings' Gross Margin rose 101900.0% to 72.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 69.65%, marking a year-over-year increase of 101700.0%. This contributed to the annual value of 63.64% for FY2024, which is 192100.0% up from last year.
  • GeneDx Holdings' Gross Margin amounted to 72.4% in Q3 2025, which was up 101900.0% from 69.04% recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Gross Margin ranged from a high of 72.4% in Q3 2025 and a low of 81.83% during Q2 2022
  • Moreover, its 5-year median value for Gross Margin was 38.51% (2023), whereas its average is 27.4%.
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by -793600bps in 2022, then soared by 1203400bps in 2023.
  • Over the past 5 years, GeneDx Holdings' Gross Margin (Quarter) stood at 4.85% in 2021, then plummeted by -448bps to 26.61% in 2022, then soared by 301bps to 53.56% in 2023, then increased by 29bps to 69.22% in 2024, then grew by 5bps to 72.4% in 2025.
  • Its Gross Margin stands at 72.4% for Q3 2025, versus 69.04% for Q2 2025 and 67.13% for Q1 2025.